Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: May 12, 2023 (Event Date); May 16, 2023 (Filing Date)
Context: The Company is an emerging growth company focused on developing targeted therapies. This filing reports the entry into and termination of material definitive agreements with Pfizer Inc. regarding the supply of the investigational cMET inhibitor, crizotinib, for clinical trials involving the Company's PKC inhibitor, darovasertib.
Key Financial Metrics
This Form 8-K does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing focuses exclusively on contractual amendments regarding drug supply.
Material Changes and Agreements
- Amendment No. 4 to Pfizer Agreement (March 11, 2020):
- Purpose: Supports the ongoing Phase 1/2 clinical trial of darovasertib + crizotinib in metastatic uveal melanoma (MUM) patients.
- Change: Increases the quantity of crizotinib supplied by Pfizer to the Company at no cost.
- Amendment No. 1 to Second Pfizer Agreement (March 9, 2022):
- Purpose: Supports the planned potential registration-enabling Phase 2/3 clinical trial of darovasertib + crizotinib in HLA-A2(-) MUM patients.
- Change: Increases the defined quantity of crizotinib provided at no cost and defines an additional second quantity to be provided at a defined, non-refundable lump-sum cost.
- Termination of Third Pfizer Agreement (March 9, 2022):
- Action: Terminated via Amendment No. 1.
- Scope: Related to a potential Phase 1 clinical trial for darovasertib + crizotinib in cMET-driven tumors (e.g., non-small cell lung cancer, hepatocellular carcinoma).
Guidance, Outlook, and Risks
Management Commentary: The Company announced these amendments on May 16, 2023, via a press release (Exhibit 99.1). The changes facilitate the continuation and expansion of clinical trials for darovasertib in specific melanoma populations.
Risks and Contingencies: The filing notes that the summary description is qualified in its entirety by reference to the full text of the amendments, which will be filed as exhibits to the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2023. No specific financial risks or contingencies are detailed in this text.
Investor Verification Checklist
- Verify the specific "defined, non-refundable lump-sum cost" for the additional crizotinib quantity in the Second Pfizer Agreement by reviewing the full Amendment No. 1 text in the upcoming 10-Q.
- Confirm the status of the terminated Phase 1 trial for cMET-driven tumors (non-small cell lung cancer/hepatocellular carcinoma) to understand the strategic shift in trial focus.
- Review the full press release (Exhibit 99.1) for any additional context on the clinical trial timelines or enrollment goals.
- Monitor the upcoming Form 10-Q for the fiscal quarter ended June 30, 2023, for the complete legal text of the amendments and any associated financial impact.